“…Therefore, it is regarded as one of the most promising gene therapy carriers (Flotte, 2004;Mingozzi & High, 2011). However, the transduction efficiency of rAAV is relatively limited; how to improve the transduction efficiency of rAAV has been one of the hot research fields of gene therapy (Kondratov, Marsic, Mietzsch, Heilbronn, & Zolotukhin, 2016;Wang et al, 2014b;Wang et al, 2016). In our research, rAAVs of different serotypes were used to infect Hela cells.…”